中新网济南1月29日电 (陈宛婷)近日，山东省政协十三届四次会议委员集中采访活动在济南举行。来自 不同行业与领域的10位山东省政协委员结合其自身工作实践，分享履职故事，回应民众期盼，精准建言 献策，为山东高质量发展凝聚智慧力量。 赋能经济发展 "民营经济与金融机构互为鱼水、共生共荣。"山东省政协委员，中国工商银行山东省分行党委书记、行 长李峰介绍说，目前，山东民营经济贷款余额已超4万亿元(人民币，下同)。其中，该行近两年的民营 贷款年均增速接近20%，贷款余额超2800亿元。 山东省政 山东是民营经济大省，民营市场主体超过1400万家，贡献了超50%的GDP、近70%的税收、80%以上的 就业。为更好地让金融"活水"精准润泽民营经济，李峰表示，该行聚焦先进生产力、特色场景及延链展 链，2025年，其民营科技企业贷款余额突破千亿元，为60家重点民企量身定制全面金融解决方案；截至 目前，已为190条供应链上的5000多户企业提供数字供应链融资。 "济钢集团在停产后搬迁到了青岛都市圈的日照市东港区。过去济钢生产线上淌的是钢水，现在'躺'的 是火箭配件，这样就同时实现了济南高端产业的延链与日照钢铁产能的升级。"采访现 ...

Group 1 - The core viewpoint of the news is that Tongce Medical's stock price increased by 5.11% to 47.48 CNY per share, with a trading volume of 836 million CNY and a turnover rate of 4.01%, resulting in a total market capitalization of 21.237 billion CNY [1] - Tongce Medical Co., Ltd. is located in Hangzhou, established on August 30, 1995, and listed on October 30, 1996. The company primarily engages in medical service investment and dental medical services [1] - The revenue composition of Tongce Medical is as follows: medical services account for 92.84%, product sales 4.06%, construction engineering 2.72%, and others 0.38% [1] Group 2 - Among the top circulating shareholders of Tongce Medical, a fund under Southern Fund holds a significant position. The Southern CSI 500 ETF (510500) reduced its holdings by 106,700 shares in the third quarter, now holding 4.5641 million shares, which is 1.02% of the circulating shares [2] - The Southern CSI 500 ETF (510500) was established on February 6, 2013, with a latest scale of 144.69 billion CNY. Year-to-date returns are 15.26%, ranking 552 out of 5,551 in its category; over the past year, returns are 56.56%, ranking 1,089 out of 4,285; and since inception, returns are 190.06% [2] - The fund manager of Southern CSI 500 ETF (510500) is Luo Wenjie, who has a cumulative tenure of 12 years and 286 days, with total fund assets of 171.358 billion CNY. The best fund return during his tenure is 192.55%, while the worst is -47.6% [2]

Core Insights - The establishment of national regional medical centers aims to bring top-tier medical resources closer to the public in Guizhou, enhancing accessibility and quality of healthcare [1][3]. Group 1: National Regional Medical Center Development - In October 2022, the Guizhou Provincial Government signed an agreement with Zhejiang Provincial People's Hospital to jointly build a national regional medical center [1]. - The Zhejiang-Bijie Hospital was approved as the fifth batch of national regional medical center projects in July 2023, making it the only such project located outside the provincial capital in Guizhou [1][3]. Group 2: Technological Advancements and Training - Over three years, Zhejiang-Bijie Hospital has introduced 258 new technologies and projects, including the establishment of Guizhou's first 5G remote robotic surgery center [3]. - The center has successfully completed the first 5G ultra-remote robotic surgery in Southwest China, demonstrating significant advancements in medical technology [3][4]. Group 3: Impact on Healthcare Accessibility - The national regional medical center facilitates the direct transfer of advanced medical technologies and management models to Guizhou, significantly improving healthcare access for patients [4]. - By 2025, Guizhou aims to establish 150 county-level medical sub-centers, which will enhance service capabilities and address healthcare challenges in rural areas [4].

"十四五"期间，长三角生态绿色一体化发展示范区（以下简称"示范区"）已经有一批重大项目稳步推 进。"十五五"期间，示范区还将聚焦哪些重点领域，安排哪些重大项目？ 1月29日，长三角生态绿色一体化发展示范区新闻发布会举行，上海市政府副秘书长、市发展改革委主 任，长三角一体化示范区执委会主任顾军表示，2025年，长三角生态绿色一体化发展示范区重大项目建 设跑出了"加速度"，全年完成投资564.3亿元，完成年度计划的111.3%。 发布会现 场 智通财经记者 江海啸 图 对接道路将建成通车，加快推动G318上海段、G50沪渝高速拓宽改建、练西公路等项目建设，示范区整 体交通路网更加便捷。 在产业创新转型领域，依托全国一体化算力网络长三角国家枢纽节点建设，推动阿里巴巴长三角智能计 算基地、中国移动长三角（上海）5G生态谷数据中心、中国电信吴江算力调度中心等一批数据中心项 目建成投产。 在公共民生服务领域，推动上海市儿童医院示范区医学中心、复旦大学附属中山医院国家医学中心青浦 院区、嘉善新城高级中学、吴江区丝绸中专异地新建等项目建设投用，完成青浦上达中央公园北园、震 泽古镇再塑工程和嘉善历史街区改造等文旅项目建设。执委 ...

1月29日，国内健康消费行业的标杆企业卓正医疗正式启动招股，招股日期为1月29日至2月3日，预计于 2026年2月6日在港交所挂牌上市，联席保荐人为海通国际及浦银国际。公司本次拟全球发售475万股， 招股区间价为57.7-66.6港元。 收入利润逆势持续双增长 受消费信心波动影响，一向被认为"抗周期"的医疗服务业近年也开始承压。叠加近年来药品集采、取消 药品加成、DRG支付改革等医保控费政策密集落地，正迅速压缩医疗机构的利润空间，从上市公司的 财报不难看出，不少医疗机构已进入零增长甚至负增长。 而创立仅13年的卓正医疗却逆势而行实现了收入和利润的双增长：2022年至2024年，营收分别为4.7亿 元、6.9亿元及9.6亿元，复合年增长率为42.2%；公司的毛利亦在快速提升，近三年分别为4398万元、 1.3亿元及2.3亿元，复合年增长率达到126.7%；更重要的是，公司从2024年开始扭亏为盈，近三年的经 调整净利润分别为-1.23亿元、-4357万元及1070万元，2025年前八个月的经调整净利润达到1045万元， 盈利能力持续增强。经营活动净现金流持续稳健增长，近三年分别为686万元、1.24亿元及1.7 ...

考察团首先实地参观了济南生物医药港，深入了解了历城区在生物医药与大健康产业领域的战略布局与 发展成果。随后，一行人驱车前往济南齐鲁花园国际医院项目规划用地进行实地考察。 在项目现场，考察团对选址给予了高度评价。该地块不仅交通便利，更展现出巨大的发展潜力——项目 周边五公里范围内尚无大型三级综合医院，医疗资源供给存在显著缺口，市场前景广阔。尤为引人注目 的是，项目毗邻济南中央商务区（CBD），站在规划中的医院地块上，即可远眺正在拔地而起的CBD 摩天大楼群。这一独特的区位优势，为未来医院打造集高端医疗、国际商务与现代生活于一体的综合性 健康服务中心奠定了坚实基础。考察团成员纷纷表示："这里视野开阔，区位优越，与城市核心区紧密 相连，对医院未来的运营和发展充满信心。" 2026年1月23日上午，济南生物医药港内暖意融融，一场聚焦国际医疗前沿的合作盛会在此举行。济南 齐鲁花园国际医院项目（筹）与日本公益财团法人神户国际医疗交流财团、日优采株式会社正式签署 《战略合作备忘录》，标志着这一备受瞩目的国际医疗合作项目进入实质性推进的新阶段。 签约仪式前，由历城区委常委、副区长文海生同志带队，区投资促进局、区卫健局、东风街 ...

Core Viewpoint - The article highlights the significant divergence in performance among various sectors in the Chinese stock market during Q4 2025, with technology and growth sectors like AI computing and semiconductors outperforming traditional sectors such as real estate and pharmaceuticals [1][2][4]. Summary by Sections Market Performance - In Q4 2025, the Shanghai Composite Index rose by 2.22%, while the CSI 300 Index fell by 0.23%, and the ChiNext Index decreased by 1.08%. The Hang Seng Index dropped by 4.56%, and the Hang Seng China Enterprises Index fell by 6.72% [1]. Fund Manager Strategies - Star fund managers like Fu Pengbo and Li Xiaoxing achieved significant excess returns, with Fu's Ruiyuan Growth Value Fund and Li's Yinhua Small Cap Select both rising over 60% in 2025, driven by heavy investments in AI computing and semiconductors [1][2]. - Balanced allocation funds, such as Zhu Shaoxing's Fuguo Tianhui Select Growth A, showed stable performance with over 20% annual growth, benefiting from diversified holdings across multiple sectors [2][12]. Technology Growth Focus - Funds focusing on technology growth, like those managed by Fu Pengbo and Xie Zhiyu, saw rewards for their strategies, with increased allocations to data center cooling, storage, and computing-related companies [4][5]. - Li Xiaoxing emphasized AI as a key investment theme, with a strong focus on semiconductor companies, indicating a shift towards domestic advanced processes and military-civilian integration opportunities [6]. Traditional Value Sector - Fund managers like Zhang Kun and Liu Yanhun maintained positions in traditional sectors like consumer goods and pharmaceuticals, facing significant net value pressure in Q4 2025. Liu's fund saw a decline of 5.85% in Q4, while Zhang's fund remained stable but adjusted sector allocations [8][10]. - Despite challenges, the pharmaceutical sector showed signs of improvement due to policy changes and innovation, with opportunities emerging in innovative drug chains and medical devices [9][10]. Consensus Among Fund Managers - Despite differing investment styles, fund managers shared common views on the impact of "anti-involution" policies on corporate fundamentals and the relative attractiveness of equity assets in the current market environment [16][17]. - The importance of stock selection has increased significantly, with a focus on identifying core companies with competitive advantages in both growth and value sectors [17].

Core Viewpoint - Zhuozheng Medical (2677.HK) has officially launched its IPO, with the offering period from January 29 to February 3, 2026, and plans to list on the Hong Kong Stock Exchange on February 6, 2026, aiming to issue 4.75 million shares at a price range of HKD 57.7 to HKD 66.6 [2] Group 1: Company Financials - Zhuozheng Medical's revenue for 2022, 2023, and 2024 is projected to be RMB 470 million, RMB 690 million, and RMB 960 million, respectively, with a compound annual growth rate (CAGR) of 42.2% [3] - The company's gross profit has also seen rapid growth, with figures of RMB 43.98 million, RMB 130 million, and RMB 230 million over the same period, achieving a CAGR of 126.7% [3] - The company is expected to turn profitable starting in 2024, with adjusted net profits of RMB -123 million, RMB -43.57 million, and RMB 10.7 million for the three years, and an adjusted net profit of RMB 10.45 million for the first eight months of 2025 [3] Group 2: Revenue Sources and Market Position - Unlike most medical institutions that rely heavily on national health insurance payments, Zhuozheng Medical's revenue from national health insurance accounted for only 0.2%, 0.2%, and 1.2% of total revenue in 2022, 2023, and 2024, respectively, indicating minimal impact from health insurance cost control policies [3] - The company has a strong customer retention rate, with membership renewal rates of approximately 42%, 56%, 64%, and 67% for the years ending December 31, 2022, 2023, and 2024, and for the eight months ending August 31, 2025, respectively [3] - Patient return rates have also been robust, recorded at 75.7%, 78.2%, 80.0%, and 82.7% for the same periods [3]

Group 1: Company Overview - Dazhu CNC Technology Co., Ltd. is a leading provider of PCB production equipment solutions in China, focusing on R&D, production, and sales of specialized equipment for PCB manufacturing. The company operates in sectors such as server and data storage, automotive electronics, mobile phones, computers, and consumer electronics. According to Zhaoshang Consulting, it holds a 10.1% market share in the PCB production equipment manufacturing sector in China as of 2024 [3] - Muyuan Foods Co., Ltd. is a technology-driven leader in the pork industry, established in 1992. The company operates through two main business segments: (i) pig farming, which includes the breeding and sale of commercial pigs, piglets, and breeding pigs, and (ii) meat processing, which involves the slaughtering and sale of pork products [9] - Distinct Healthcare Holdings Limited focuses on providing high-end medical services, targeting affluent consumers who prefer personalized healthcare. The company operates 19 medical institutions across major cities in China and has clinics in Singapore and Malaysia [15][16] Group 2: IPO Details - Dazhu CNC plans to offer 50.45 million shares globally, with 10% allocated for Hong Kong and 90% for international sales. The maximum offer price is set at HKD 95.8 per share, with an expected trading start date of February 6, 2026 [1] - Muyuan Foods intends to issue 274 million shares, with a maximum offer price of HKD 39.00 per share. The shares are also expected to start trading on February 6, 2026 [7] - Distinct Healthcare plans to offer 4.75 million shares, with a price range of HKD 57.7 to 66.6 per share, and is expected to begin trading on February 6, 2026 [13] Group 3: Financial Performance - Dazhu CNC's revenue for the years 2022, 2023, and 2024 was RMB 2.786 billion, RMB 1.634 billion, and RMB 3.343 billion, respectively. The net profit for the same years was RMB 432 million, RMB 136 million, and RMB 300 million [6] - Muyuan Foods reported revenues of RMB 124.826 billion, RMB 110.861 billion, and RMB 137.947 billion for the years 2022, 2023, and 2024, respectively. The net profit for these years was RMB 14.933 billion, a loss of RMB 4.168 billion, and RMB 18.925 billion [12] - Distinct Healthcare's revenue for 2022, 2023, and 2024 was RMB 473 million, RMB 690 million, and RMB 959 million, respectively. The company experienced a net loss of RMB 222 million in 2022, which increased to RMB 353 million in 2023, but achieved a net profit of RMB 80 million in 2024 [18]

省政协八届四次会议第二场"委员通道"彰显自贸港开放度 "请到天涯海角来" 海南日报全媒体记者 易宗平 陈成智 省政协委员，省对外交流服务中心主任、研究员邓颖颖在讲述国际青少年交流时，提到了一首歌。 在漫长的岁月里，无数人曾因为这首歌寻梦天涯、流连海角。 没错，邓颖颖提到的歌，正是《请到天涯海角来》。 1月28日，伴随着邓颖颖的讲述，省政协八届四次会议第二场"委员通道"在海口如期举行。 包括邓颖颖在内，8名来自不同界别的政协委员带来的，是比《请到天涯海角来》旋律更澎湃的"海 南故事"，是比歌词更深邃的"自贸港思考"。 天涯沃土结硕果 "请到天涯海角来，这里花果遍地栽……" 如今的海南，结的可不只是热带瓜果，更是海南自贸港高质量发展硕果。 "2025年末，海南控股资产规模达到2270亿元，营收规模突破800亿元，5年来累计贡献财税超170亿 元……"这是十四届全国政协委员、省政协常委、省发展控股有限公司总经理李国红透露的数据。 释放发展活力、扩大共享成果，需要市场"无形之手"与政府"有形之手"相握。 "准入更快、退出更顺、准营更简、服务更优"，省政协委员、省市场监管局登记注册局局长陈术颖 的"四个更"承诺，背后是 ...